U.S. Semaglutide Market Size & Outlook, 2026-2035
Global Market
Related Markets
U.S. semaglutide market highlights
- The U.S. semaglutide market generated a revenue of USD 23,325.3 million in 2025 and is expected to reach USD 57,964.7 million by 2035.
- The U.S. market is expected to grow at a CAGR of 8.83% from 2026 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2025.
- Ozempic (semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
Semaglutide market data book summary
| Market revenue in 2025 | USD 23,325.3 million |
| Market revenue in 2035 | USD 57,964.7 million |
| Growth rate | 8.83% (CAGR from 2026 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Ozempic (semaglutide) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Viking Therapeutics Inc, Lexicon Pharmaceuticals, Biocon, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, U.S. accounted for 67.5% of the global semaglutide market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2035.
- In North America, U.S. semaglutide market is projected to lead the regional market in terms of revenue in 2035.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 629.4 million by 2035.
The U.S. dominates the North America semaglutide market, driven by increasing demand for GLP-1 receptor agonists in diabetes and obesity management. Early regulatory approvals, and extensive R&D activities contribute to market expansion.
The rising adoption of semaglutide for weight loss, despite its primary approval for diabetes, is reshaping prescribing trends. Retail pharmacies are the dominant distribution channel, with online pharmacies gaining traction due to convenience and direct-to-consumer models.
No credit card required*
Publish Date: Apr 16, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Semaglutide Market Scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | www.biocon.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | www.vikingtherapeutics.com |
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | www.lexpharma.com |
U.S. Semaglutide Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Semaglutide Market Outlook will help companies and investors design strategic landscapes.
Ozempic (Semaglutide) was the largest segment with a revenue share of 69.42% in 2025.
Horizon Databook has segmented the U.S. semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2021 to 2035.
The U.S. dominates the North America semaglutide market, driven by increasing demand for GLP-1 receptor agonists in diabetes and obesity management. Early regulatory approvals, and extensive R&D activities contribute to market expansion.
The rising adoption of semaglutide for weight loss, despite its primary approval for diabetes, is reshaping prescribing trends. Retail pharmacies are the dominant distribution channel, with online pharmacies gaining traction due to convenience and direct-to-consumer models.
- U.S. Semaglutide Market Product Outlook (Revenue, USD Million , 2021-2035)
- Ozempic (semaglutide)
- Wegovy (semaglutide)
- Rybelsus (oral semaglutide)
- Others
- U.S. Semaglutide Market Application Outlook (Revenue, USD Million , 2021-2035)
- Type 2 Diabetes Mellitus
- Obesity
- U.S. Semaglutide Market Route of Administration Outlook (Revenue, USD Million , 2021-2035)
- Parenteral
- Oral
- U.S. Semaglutide Market Distribution Channel Outlook (Revenue, USD Million , 2021-2035)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Reasons to subscribe to Semaglutide Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Semaglutide Market Outlook databook
- Our clientele includes a mix of Semaglutide Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Semaglutide Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Semaglutide Market Outlook from 2021 to 2035, including revenue numbers, major trends, and company profiles.
U.S. Semaglutide Market, 2021-2035 (US$M)
U.S. semaglutide market statistics, by product, 2021-2035 (US$M)
